Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: Clinical significance and implications for decision making- A position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society

Europace

Volumn 17, Issue 8, 2015, Pages 1169-1196

  Boriani, Giuseppe ^a   Savelieva, Irina ^b   Dan, Gheorghe Andrei ^b   Deharo, Jean Claude ^b   Ferro, Charles ^b   Israel, Carsten W ^b   Lane, Deirdre A ^b   La Manna, Gaetano ^a   Morton, Joseph ^b   Mitjans, Angel Moya ^b   Vos, Marc A ^b   Turakhia, Mintu P ^b   Lip, Gregory Y H ^b   Gorenek, Bulent ^b   Takahashi, Yoshihide ^b   Lau, Dennis ^b   Chung, Mina ^b   Nielsen, Jens Cosedis ^b   Fauchier, Laurent ^b   Potpara, Tatjana ^b   Marin, Francisco ^b   Kudaiberdieva, Gulmira ^b   Hindricks, Gerhard ^b   Linde, Cecilia ^b   Brignole, Michele ^a   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE   (Sweden)

Author keywords

Arrhythmias; Atrial fibrillation; Cardiac implantable electrical devices; Cardiac resynchronization therapy; Chronic kidney disease; Dialysis; Drugs; Epidemiology; Hemodialysis; Implantable cardioverter defibrillator; Infection; Pacemaker; Sudden cardiac death; Ventricular tachyarrhythmias

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACUTE KIDNEY FAILURE; ARRHYTHMOGENESIS; ATRIAL FIBRILLATION; BLEEDING; BRADYCARDIA; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTRAST INDUCED NEPHROPATHY; DISEASE COURSE; ELECTROLYTE DISTURBANCE; FAINTNESS; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE TACHYCARDIA; HEMODIALYSIS; HEMODYNAMICS; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KIDNEY FUNCTION; LIFE EXPECTANCY; LONG TERM CARE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; TERMINAL CARE; THROMBOEMBOLISM; ARRHYTHMIAS, CARDIAC; ASIA; CARDIO-RENAL SYNDROME; CARDIOLOGY; CLINICAL DECISION MAKING; COMPLICATION; EUROPE; KIDNEY FUNCTION TEST; PRACTICE GUIDELINE; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; STANDARDS;

ARRHYTHMIAS, CARDIAC; ASIA; CARDIO-RENAL SYNDROME; CARDIOLOGY; CLINICAL DECISION-MAKING; DEFIBRILLATORS, IMPLANTABLE; EUROPE; HUMANS; KIDNEY FUNCTION TESTS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84939599683     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv202     Document Type: Review

References (258)

1. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Kö ttgen A, Levey AS et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158-69
2. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379:165-80
3. Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: Things are seldom what they seem. Eur Heart J 2014;35:416-8
4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382:339-52
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKDWork Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;3(Suppl):1-150
6. CockcroftDW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
7. Michels WM, Grootendorst DG, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010;5:1003-9
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70
9. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150: 604-12
10. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: A systematic review. Ann Intern Med 2012;156:785-95
11. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. Current and novel renal biomarkers in heart failure. Heart Fail Rev 2012;17:241-50
12. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE et al. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010;375:2073-81
13. van der Velde M, Matsushita K, Coresh J, Astor BC,Woodward M, Levey A et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of highrisk population cohorts. Kidney Int 2011;79:1341-52
14. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011;79:1331-40
15. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266
16. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-130
17. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47
18. Anandarajah S, Tai T, de Lusignan S, Stevens P, O'Donoghue D, Walker M et al. The validity of searching routinely collected general practice computer data to identify patients with chronic kidney disease (CKD): A manual review of 500 medical records. Nephrol Dial Transplant 2005;20:2089-96
19. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006;17:2275-84
20. Zhang L, Zhang P,Wang F, Zuo L, Zhou Y, Shi Y et al. Prevalence and factors associated with CKD: A population study from Beijing. Am J Kidney Dis 2008;51: 373-84
21. White SL, Polkinghorne KR, Atkins RC, Chadban SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: The AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis 2010;55:660-70
22. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009;13:621-30
23. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in populationbased studies: systematic review. BMC Public Health 2008;8:117
24. Otero A, de Francisco A, Gayoso P, Garcia F, Group ES. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia 2010;30:78-86
25. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-305
26. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007;28:478-83
27. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-63
28. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-119
29. U. S. Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethseda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006
30. Mafham M, Emberson J, Landray MJ,Wen CP, Baigent C. Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: A meta-analysis. PLoS ONE 2011;6:e25920
31. Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 2010;96:817-23
32. Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. Heart 2013;99:365-72
33. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-39
34. Cruz DN, Schmidt-Ott KM, Vescovo G, House AA, Kellum JA, Ronco C et al. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013;182:117-36
35. Tumlin JA, Costanzo MR, Chawla LS, Herzog CA, Kellum JA, McCullough PA et al. Cardiorenal syndrome type 4: insights on clinical presentation and pathophysiology from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013;182:158-73
36. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. J Card Fail 2007;13:422-30
37. Hebert K, Dias A, Delgado MC, Franco E, Tamariz L, Steen D et al. Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population. Eur J Heart Fail 2010;12:861-5
38. Cruz DN, Bagshaw SM. Heart-kidney interaction: epidemiology of cardiorenal syndromes. Int J Nephrol 2010;2011:351291
39. Crews DC, Plantinga LC, Miller ER III, Saran R, Hedgeman E, Saydah SH et al. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. Hypertension 2010;55:1102-9
40. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213-20
41. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
42. Boriani G, Diemberger I, Martignani C, Biffi M, Branzi A. The epidemiological burden of atrial fibrillation: A challenge for clinicians and healthcare systems. Eur Heart J 2006;27:893-4
43. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123:2946-53
44. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation 2012;126:e143-6
45. Lip GY, Laroche C, Boriani G, Cimaglia P, Dan GA, Santini M et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: A report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace 2015;17:24-31
46. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH et al. Asymptomatic atrial fibrillation: clinical correlates, management and outcomes in the EORP-AF Pilot General Registry. Am J Med 2015;128:509-18
47. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA et al. Heart failure in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail 2015; doi: 10. 1002/ejhf. 254
48. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. Am Heart J 2009;158:629-36
49. Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int 2012;81:469-76
50. Goldstein BA, Arce CM, Hlatky MA, Turakhia M, Setoguchi S, Winkelmayer WC. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 2012;126:2293-301
51. Winkelmayer WC, Liu J, Patrick AR, Setoguchi S, Choudhry NK. Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis. J Nephrol 2012;25:341-53
52. Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5:173-81
53. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M et al. Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102-7
54. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellanWet al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011;4:26-32
55. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367: 625-35
56. Wong JA, Goodman SG, Yan RT, Wald R, Bagnall AJ, Welsh RC et al. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. Eur Heart J 2009;30:549-57
57. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: A report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010;121:357-65
58. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69
59. Fox CS, Matsushita K,Woodward M, Bilo HJ, Chalmers J, Heerspink HJ et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis. Lancet 2012;380: 1662-73
60. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: A meta-analysis. Lancet 2012; 380:1649-61
61. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-95
62. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006;144:172-80
63. Menon V,Wang X, Sarnak MJ, Hunsicker LH, Madero M, Beck GJ et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int 2008;73:1310-5
64. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997;51:1908-19
65. Haroun MK, Jaar BG, Hoffman SC, ComstockGW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: A prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003;14:2934-41
66. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003;14:479-8
67. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011;305:1553-9
68. Bansal N, Alce D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 2013;127:569-74
69. Chiu PF, Huang CH, Liou HH,WuCL, Chang C, Chang CC et al. Lower-dose warfarin delays renal progression and prolongs patient survival in patients with stage 3-5 chronic kidney disease and nonvalvular atrial fibrillation: A 12-year follow-up study. Int J Clin Pharmacol Ther 2014;52:504-8
70. Chang CC, Liou HH, Wu CL, Chang CB, Chang YJ, Chiu PF et al. Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation. Clin Interv Aging 2013;8:523-9
71. Roberts PR, Green D. Arrhythmias in chronic kidney disease. Heart 2011;97: 766-73
72. Poulikakos D, Banerjee D, Malik M. Risk of sudden cardiac death in chronic kidney disease. J Cardiovasc Electrophysiol 2014;25:222-31
73. Middleton JP. Predisposition to arrhythmias: electrolytes, uremic fibrosis, other factors. Semin Dial 2011;24:287-9
74. El-Sherif N, Turitto G Electrolyte disturbances and arrhythmogenesis. Cardiol J 2011;18:233-45
75. Turakhia MP, Schiller NB, Whooley MA. Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). Am J Cardiol 2008;102: 1131-5
76. Zaza A. Serum potassium and arrhythmias. Europace 2009;11:421-2
77. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU et al. Drug dosing consideration in patients with acute and chronic kidney disease- a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;80:1122-37
78. Kaski JC, Baker S, Hayward C, Khong TK, Mahida S, Tamargo J (eds). Drugs in Cardiology: A Comprehensive Guide to Cardiovascular Pharmacotherapy. London, UK: Oxford University Press; 2010
79. Heidbuchel H, Verhamme P, Alings M, AntzM, HackeW, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51
80. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413
81. Providência R, Marijon E, Boveda S, Barra S, Narayanan K, Le Heuzey JY et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol 2014; 114:646-53
82. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196-203
83. Kooiman J, van Rein N, Spaans B, van Beers KAJ, Bank JR, van de Peppel Wet al. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in nondialysis dependent chronic kidney disease. PLoS ONE 2014;9:e94420
84. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: The Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015;36:297-306
85. Chao TF, Liu CJ,Wang KL, Lin YJ, Chang SL, Lo LWet al. Incidence and prediction of ischaemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 2014;11:1752-9
86. Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M et al. Renal impairment in a 'real-life' cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013;111: 1159-64
87. Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 2013;61:2079-87
88. Apostolakis S, Guo Y, Lane DA, Buller H, Lip GYH. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: The AMADEUS trial. Eur Heart J 2013;34:3572-9
89. Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. Chest 2014; 145:1370-82
90. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 2009;119:1363-9
91. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014;129: 961-70
92. Eikelboom JW, Connolly SJ, Gao P, Paolasso E, De Caterina R, Husted S et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012;21:429-35
93. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33:2821-30
94. Fox KA, Piccini JP,Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94
95. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013;127:224-32
96. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, UdaltsovaNet al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J Am Heart Assoc 2013;2:e000250
97. Kornej J, Hindricks G, Kosiuk J, Arya A, Sommer P, Husser D et al. Comparison of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol 2014;7:281-7
98. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. J Am Coll Cardiol 2014;64:1658-65
99. Lip GY, Nielsen PB, Skjøth F, LaneDA, Rasmussen LH, Larsen TB. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: A nationwide cohort study. Chest 2014;146:1337-46
100. Roldán V, Maŕn F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013;109:956-60
101. Guo Y,Wang H, Zhao X, Zhang Y, Zhang D, Ma J et al. Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation. Int J Cardiol 2013;168:1502-8
102. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT2R2 score. Chest 2013;144:1555-63
103. De Caterina R, Husted S,Wallentin L, Andreotti F, Arnesen H, Bachmann F et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087-107
104. Gallego P, Roldan V, Maŕn F, Romera M, Valdés M, Vicente V et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013;110:1189-98
105. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-100
106. Lip GY, Frison L, Grind M, SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007;28:752-9
107. Lip GY, Frison L, Grind M. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation. J Intern Med 2007;261:577-86
108. Verdecchia P, Reboldi G, Di Pasquale G, Mazzotta G, Ambrosio G, Yang S et al. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol 2014;113:669-75
109. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003;41: 218-23
110. Konecny T, Park JY, Somers KR, Konecny D, Orban M, Soucek F et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 2014;114:272-7
111. Ganga HV, Nair SU, Puppala VK, Miller WL. Risk of new-onset atrial fibrillation in elderly patients with the overlap syndrome: A retrospective cohort study. J Geriatr Cardiol 2013;10:129-34
112. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL et al. Incidence and risk of atrial fibrillation in sleep-disordered breathing without coexistent systemic disease. Circ J 2014;78:2182-7
113. Yazdan-Ashoori P, Baranchuk A. Obstructive sleep apnea may increase the risk of stroke in AF patients: refining the CHADS2 score. Int J Cardiol 2011;146:131-3
114. Goyal SK, Wang L, Upender R, Darbar D, Monahan K. Severity of obstructive sleep apnea influences the effect of genotype on response to anti-arrhythmic drug therapy for atrial fibrillation. J Clin Sleep Med 2014;10:503-7
115. Sano F, Ohira T, Kitamura A, Imano H, Cui R, Kiyama M et al. Heavy alcohol consumption and risk of atrial fibrillation. The Circulatory Risk in Communities Study (CIRCS). Circ J 2014;78:955-61
116. Larsson SC, Drca N,Wolk A. Alcohol consumption and risk of atrial fibrillation: A prospective study and dose-response meta-analysis. J Am Coll Cardiol 2014;64: 281-9
117. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Albertsen IE, Lane DA et al. Alcohol intake and prognosis of atrial fibrillation. Heart 2013;99:1093-9
118. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med 2013; 126:640
119. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial. JAMA 2013;310:2050-60
120. Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002;141:191-7
121. Herzog CA, Li S,Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005;68:818-25
122. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 2003;16:111-7
123. Parekh RS, Plantinga LC, Kao WH, Meoni LA, Jaar BG, Fink NE et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 2008;74:1335-42
124. Wang AY, LamCW, Chan IH,Wang M, Lui SF, Sanderson JE. Sudden cardiac death in end-stage renal disease patients: A 5-year prospective analysis. Hypertension 2010;56:210-6
125. Genovesi S, Rossi E, Nava M, Riva H, De Franceschi S, Fabbrini P et al. A case series of chronic haemodialysis patients: mortality, sudden death, and QT interval. Europace 2013;15:1025-33
126. Goldenberg I, Moss AJ, McNitt S, ZarebaW, Andrews ML, Hall WJ et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006;98:485-90
127. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006;114:2766-72
128. Deo R, Lin F, Vittinghoff E, Tseng ZH, Hulley SB, Shlipak MG. Kidney dysfunction and sudden cardiac death among women with coronary heart disease. Hypertension 2008;51:1578-82
129. Pun PH, Smarz TR, Honeycutt EF, Shaw LK, Al-Khatib SM, Middleton JP. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009;76:652-8
130. Davis TR, Young BA, Eisenberg MS, Rea TD, Copass MK, Cobb LA. Outcome of cardiac arrests attended by emergency medical services staff at community outpatient dialysis centers. Kidney Int 2008;73:933-9
131. Whitman IR, Feldman HI, Deo R. CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. J Am Soc Nephrol 2012;23:1929-39
132. de Bie MK, Buiten MS, Rabelink TJ, Jukema JW. How to reduce sudden cardiac death in patients with renal failure. Heart 2012;98:335-41
133. Edwards NC, Steeds RP, Ferro CJ, Townend JN. The treatment of coronary artery disease in patients with chronic kidney disease. QJM 2006;99:723-36
134. Charytan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J 2006;152:558-64
135. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004;65:2380-9
136. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009;4(Suppl 1):S79-91
137. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001;12:1079-84
138. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005;46:320-7
139. Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: The role of cardiovascular magnetic resonance. JACC Cardiovasc Imaging 2014;7:703-14
140. Jaroszynski A, Czekajska-Chechab E, Drelich-Zbroja A, Zapolski T, Ksiazek A. Spatial QRS-T angle in peritoneal dialysis patients: Association with carotid artery atherosclerosis, coronary artery calcification and troponin T. Nephrol Dial Transplant 2009;24:1003-8
141. de Bie MK, Koopman MG, Gaasbeek A, Dekker FW, Maan AC, Swenne CA et al. Incremental prognostic value of an abnormal baseline spatial QRS-T angle in chronic dialysis patients. Europace 2013;15:290-6
142. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-8
143. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998;11(6 Pt 1):723-8
144. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002;105:1354-9
145. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int 1999;55:1553-9
146. Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006;69:2268-73
147. Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011;365: 1099-107
148. Perl J, Chan CT. Timing of sudden death relative to the hemodialysis procedure. Nat Clin Pract Nephrol 2006;2:668-9
149. de Bie MK, van Dam B, Gaasbeek A, van Buren M, van Erven L, Bax JJ et al. The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. Eur Heart J 2009;30:1559-64
150. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM et al. Cardiac arrest and sudden death in dialysis units. Kidney Int 2001;60:350-7
151. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13
152. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-7
153. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:550-60
154. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006;70:2021-30
155. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006;296: 1377-84
156. Chonchol M, Benderly M, Goldbourt U. Beta-blockers for coronary heart disease in chronic kidney disease. Nephrol Dial Transplant 2008;23:2274-9
157. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G, Cholesterol and Recurrent Events Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003;138: 98-104
158. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009;2:CD007784
159. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011;377:2181-92
160. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO et al. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am J Kidney Dis 2011;57:403-14
161. Pun PH, Lehrich RW, Smith SR, Middleton JP. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007;2:491-500
162. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341: 709-17
163. Pun PH, LehrichRW, Honeycutt EF, Herzog CA, Middleton JP. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 2011;79:218-27
164. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA 2007;298:1291-9
165. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ et al. Incenter hemodialysis six times per week versus three times per week. N Engl J Med 2010;363:2287-300
166. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, EstesNA 3rd et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:104-23
167. Nimmo C, Wright M, Goldsmith D. Management of atrial fibrillation in chronic kidney disease: double trouble. Am Heart J 2013;166:230-9
168. Palmer BF, Henrich WL. Recent advances in the prevention and management of intradialytic hypotension. J Am Soc Nephrol 2008;19:8-11
169. Stefansson BV, Brunelli SM, Cabrera C, Rosenbaum D, Anum E, Ramakrishnan K et al. Intradialytic hypotension and risk of cardiovascular disease. Clin J Am Soc Nephrol 2014;9:2124-32
170. Henderson LW. Symptomatic intradialytic hypotension and mortality: An opinionated review. Semin Dial 2012;25:320-5
171. Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol 2015;26: 724-34
172. Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int 2008; 73:759-64
173. Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): A randomized, controlled trial. Hypertension 2009; 53:500-7
174. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012;379:648-61
175. Boriani G, Biffi M, Diemberger I, Martignani C, Branzi A. Rate control in atrial fibrillation: choice of treatment and assessment of efficacy. Drugs 2003;63: 1489-509
176. Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A et al. Personalized management of atrial fibrillation: proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013;15:1540-56
177. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-73
178. Talajic M, Khairy P, Levesque S, Connolly SJ, Dorian P, Dubuc M et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol 2010;55:1796-802
179. Szczech LA. Atrial fibrillation: The beat is faster than the answers. Kidney Int 2012; 81:432-3
180. Ng KP, Edwards NC, Lip GY, Townend JN, Ferro CJ. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am J Kidney Dis 2013;62:615-32
181. Navaravong L, Barakat M, Burgon N, Mahnkopf C, Koopmann M, Ranjan R et al. Improvement in estimated glomerular filtration rate in patients with chronic kidney disease undergoing catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2015;26:21-7
182. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial. JAMA 2010;303:333-40
183. Haegeli LM, Calkins H. Catheter ablation of atrial fibrillation: An update. Eur Heart J 2014;35:2454-9
184. Naruse Y, Tada H, Sekiguchi Y, Machino T, Ozawa M, Yamasaki H et al. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: A mid-term follow-up. Heart Rhythm 2011;8: 335-41
185. Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Hirayama H et al. Outcomes of ablation of paroxysmal atrial fibrillation in patients on chronic hemodialysis. J Cardiovasc Electrophysiol 2012;23:1289-94
186. Hayashi M, Kaneko S, Shimano M, Ohashi T, Kubota R, Takeshita K et al. Efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in chronic hemodialysis patients. Nephrol Dial Transplant 2014;29:160-7
187. Takigawa M, Kuwahara T, Takahashi A, Kobori A, Takahashi Y, Okubo K et al. The impact of haemodialysis on the outcomes of catheter ablation in patients with paroxysmal atrial fibrillation. Europace 2014;16:327-34
188. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307-15
189. Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Hert SD et al. 2014 ESC/ ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014;35:2383-431
190. Shastri S, Sarnak MJ. Cardiovascular disease and CKD: core curriculum 2010. Am J Kidney Dis 2010;56:399-417
191. Trainor D, Borthwick E, Ferguson A. Perioperative management of the hemodyalisis patient. Semin Dial 2011;24:314-26
192. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999;100:1043-9
193. KDOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45(4 Suppl 3):S1-153
194. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: The task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC)European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA). Europace 2013;15: 1070-118
195. Hercé B, Nazeyrollas P, Lesaffre F, Sandras R, Chabert JP, Martin A et al. Risk factors for infection of implantable cardiac devices: data from a registry of 2496 patients. Europace 2013;15:66-70
196. Vanerio G, Garcá C, González C, Ferreiro A. Mortality in patients on renal replacement therapy and permanent cardiac pacemakers. Int J Nephrol 2014;2014: 284172
197. Barold SS, Falkoff MD, Ong LS, Heinle RA. Hyperkalemia-induced failure of atrial capture during dual-chamber cardiac pacing. J Am Coll Cardiol 1987;10:467-9
198. Kahloon MU, Aslam AK, Aslam AF, Wilbur SL, Vasavada BC, Khan IA. Hyperkalemia induced failure of atrial and ventricular pacemaker capture. Int J Cardiol 2005; 105:224-6
199. Boriani G, Rusconi L, Biffi M, Pavia L, Sassara M, Malfitano D et al. Role of ventricular autocapture function in increasing longevity of DDDR pacemakers: A prospective study. Europace 2006;8:216-20
200. Tan CS, Jie C, Joe J, Irani ZD, Ganguli S, Kalva SP et al. The impact of transvenous cardiac devices on vascular access patency in hemodialysis patients. Semin Dial 2013;26:728-32
201. Cannizzaro LA, Piccini JP, Patel UD, Hernandez AF. Device therapy in heart failure patients with chronic kidney disease. J Am Coll Cardiol 2011;58:889-96
202. Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. Am J Cardiol 2010;105:1140-6
203. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49
204. Shalaby A, El-Saed A, Voigt A, Albany C, Saba S. Elevated serum creatinine at baseline predicts poor outcome in patients receiving cardiac resynchronization therapy. Pacing Clin Electrophysiol 2008;31:575-9
205. van Bommel RJ, Borleffs CJ, Ypenburg C, Marsan NA, Delgado V, Bertini M et al. Morbidity and mortality in heart failure patients treated with cardiac resynchronization therapy: influence of pre-implantation characteristics on long-term outcome. Eur Heart J 2010;31:2783-90
206. Goldenberg I, Moss AJ, McNitt S, Barsheshet A, Gray D, Andrews ML et al. Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Heart Rhythm 2010;7:1777-82
207. Lin G, Gersh BJ, Greene EL, Redfield MM, Hayes DL, Brady PA. Renal function and mortality following cardiac resynchronization therapy. Eur Heart J 2011;32: 184-90
208. Mathew J, Katz R, St John Sutton M, Dixit S, Gerstenfeld EP, Ghio S et al. Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail 2012;14:1420-8
209. Friedman DJ, Upadhyay GA, Singal G, Orencole M, Moore SA, Parks KA et al. Usefulness and consequences of cardiac resynchronization therapy in dialysisdependent patients with heart failure. Am J Cardiol 2013;112:1625-31
210. Hosoda J, Ishikawa T, Matsushita K, Matsumoto K, Kimura Y, Miyamoto M et al. Impact of renal insufficiency on long-term clinical outcome in patients with heart failure treated by cardiac resynchronization therapy. J Cardiol 2012;60:301-5
211. Garg N, Thomas G, Jackson G, Rickard J, Nally JV Jr, Tang WH et al. Cardiac resynchronization therapy in CKD: A systematic review. Clin J Am Soc Nephrol 2013;8: 1293-303
212. Korantzopoulos P, Liu T, Li L, Goudevenos JA, Li G. Implantable cardioverter defibrillator therapy in chronic kidney disease: A meta-analysis. Europace 2009;11: 1469-75
213. Sakhuja R, Keebler M, Lai TS, McLaughlin Gavin C, Thakur R, Bhatt DL. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. Am J Cardiol 2009;103:735-41
214. Hage FG, Aljaroudi W, Aggarwal H, Bhatia V, Miller J, Doppalapudi H et al. Outcomes of patients with chronic kidney disease and implantable cardiac defibrillator: primary versus secondary prevention. Int J Cardiol 2013;165:113-6
215. Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: A meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis 2014;64:32-9
216. Hess PL, Hellkamp AS, Peterson ED, Sanders GD, Al-Khalidi HR, Curtis LH et al. Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. Circ Arrhythm Electrophysiol 2014;7:793-9
217. Makki N, Swaminathan PD, Hanmer J, Olshansky B. Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies. Europace 2014; 16:55-62
218. Buiten MS, De Bie MK, Van Der Heijden AC, Rotmans JI, Bootsma M, Marc Groeneveld JH et al. Chronic kidney disease and implantable cardioverter defibrillator related complications: 16 years of experience. J Cardiovasc Electrophysiol 2014;25:998-1004
219. Eisen A, Suleiman M, Strasberg B, Sela R, Rosenheck S, Freedberg NA et al. Renal dysfunction and clinical outcomes of patients undergoing ICD and CRTD implantation: data from the Israeli ICD registry. J Cardiovasc Electrophysiol 2014;25:990-7
220. Genovesi S, Porcu L, Luise MC, Riva H, Nava E, Stella A et al. Mortality, sudden death and indication for cardioverter defibrillator implantation in a dialysis population. Int J Cardiol 2015;186:170-7
221. Williams ES, Shah SH, Piccini JP, Sun AY, Koontz JI, Al-Khatib SM et al. Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: An EPGEN substudy. Europace 2011;13:1717-22
222. Barsheshet A, Moss AJ, Huang DT, McNitt S, ZarebaW, Goldenberg I. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter defibrillator. J Am Coll Cardiol 2012;58:2075-9
223. Amin MS, Fox AD, Kalahasty G, Shepard RK,Wood MA, Ellenbogen KA. Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: A decision model analysis. J Cardiovasc Electrophysiol 2008;19:1275-80
224. Lambiase PD, Barr C, Theuns DA, Knops R, Neuzil P, Johansen JB et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD registry. Eur Heart J 2014;35:1657-65
225. Klein HU, Goldenberg I, Moss AJ. Risk stratification for implantable cardioverter defibrillator therapy: The role of the wearable cardioverter-defibrillator. Eur Heart J 2013;34:2230-42
226. Saad TF, Hentschel DM, Koplan B,Wasse H, Asif A, Patel DV et al. Cardiovascular implantable electronic device leads in CKD and ESRDpatients: reviewand recommendations for practice. Semin Dial 2013;26:114-23
227. Saad TF, Ahmed W, Davis K, Jurkovitz C. Cardiovascular implantable electronic devices in hemodialysis patients: prevalence and implications for arteriovenous hemodialysis access interventions. Semin Dial 2015;28:94-100
228. Drew DA, Meyer KB,Weiner DE. Transvenous cardiac device wires and vascular access in hemodialysis patients. Am J Kidney Dis 2011;58:494-6
229. Charytan DM, Patrick AR, Liu J, Setoguchi S, Herzog CA, Brookhart MA et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 2011;58:409-17
230. Diemberger I, Biffi M, Martignani C, Boriani G. From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter-defibrillator systems. Expert Rev Med Devices 2011;8:235-55
231. De Maria E, Diemberger I, Vassallo PL, Pastore M, Giannotti F, Ronconi C et al. Prevention of infections in cardiovascular implantable electronic devices beyond the antibiotic agent. J Cardiovasc Med (Hagerstown) 2014;15:554-64
232. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol 2011;58:1001-6
233. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: A systematic review and meta-analysis. Europace 2015;17:767-77
234. Mittal S, Shaw RE, Michel K, Palekar R, Arshad A, Musat D et al. Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm 2014;11:595-601
235. Deharo JC, Quatre A, Mancini J, Khairy P, Le Dolley Y, Casalta JP et al. Long-term outcomes following infection of cardiac implantable electronic devices: A prospective matched cohort study. Heart 2012;98:724-31
236. Hickson LJ, Gooden JY, Le KY, Baddour LM, Friedman PA, Hayes DL et al. Clinical presentation and outcomes of cardiovascular implantable electronic device infections in hemodialysis patients. Am J Kidney Dis 2014;64:104-10
237. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3:1526-33
238. Tompkins C, McLean R, Cheng A, Brinker JA, Marine JE, Nazarian S et al. End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol 2011;22:1099-104
239. Asif A, Salman L, Lopera G, Haqqie SS, Carrillo R. Transvenous cardiac implantable electronic devices and hemodialysis catheters: recommendations to curtail a potentially lethal combination. Semin Dial 2012;25:582-6
240. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB et al. Update on cardiovascular implantable electronic device infections and their management: A scientific statement from the American Heart Association. Circulation 2010;121:458-77
241. Diemberger I, Mazzotti A, Giulia MB, Cristian M, Matteo M, Letizia ZM et al. From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. Expert Rev Med Devices 2013;10:551-73
242. Asif A, Carrillo R, Garisto JD, Monrroy M, Khan RA, Castro H et al. Prevalence of chronic kidney disease in patients undergoing cardiac rhythm device removal. Semin Dial 2013;26:111-3
243. Crossley GH, Poole JE, Rozner MA, Asirvatham SJ, Cheng A, Chung MK et al. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm 2011;8:1114-54
244. Braunschweig F, Boriani G, Bauer A, Hatala R, Herrmann-Lingen C, Kautzner J et al. Management of patients receiving implantable cardiac defibrillator shocks: recommendations for acute and long-term patient management. Europace 2010; 12:1673-90
245. Manegold JC, Israel CW, Ehrlich JR, Duray G, Pajitnev D, Wegener FT et al. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: A randomized comparison of monophasic and biphasic shock energy application. Eur Heart J 2007;28: 1731-8
246. Nazarian S, Roguin A, Zviman MM, Lardo AC, Dickfeld TL, Calkins H et al. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1. 5 tesla. Circulation 2006;114:1277-84
247. St Peter WL. Introduction: chronic kidney disease: A burgeoning health epidemic. J Manag Care Pharm 2007;13(9 Suppl D):S2-5
248. Vanholder R, Davenport A, Hannedouche T, Kooman J, Kribben A, Lameire N et al. Reimbursement of dialysis: A comparison of seven countries. J Am Soc Nephrol 2012;23:1291-8
249. Boriani G, Maniadakis N, Auricchio A, Mü ller-Riemenschneider F, Fattore G, Leyva F et al. Health technology assessment in interventional electrophysiology and device therapy: A position paper of the European Heart Rhythm Association. Eur Heart J 2013;34:1869-74
250. Maniadakis N, Vardas P, Mantovani LG, Fattore G, Boriani G. Economic evaluation in cardiology. Europace 2011;13(Suppl 2):ii3-8
251. Fattore G, Maniadakis N, Mantovani LG, Boriani G. Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. Europace 2011;13(Suppl 2):ii49-53
252. Boriani G, Diemberger I, Biffi M, Martignani C. Cost-effectiveness of cardiac resynchronisation therapy. Heart 2012;98:1828-36
253. Arribas F, Auricchio A, Boriani G, Brugada J, Deharo JC, Hindriks G et al. Statistics on the use of cardiac electronic devices and electrophysiological procedures in 55 ESC countries: 2013 report from the European Heart Rhythm Association (EHRA). Europace 2014;16(Suppl 1):i1-78
254. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382:260-72
255. Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: The TREAT randomised trial. PLoS ONE 2013;8:e74037
256. Boriani G, Diemberger I, Martignani C, Biffi M, Valzania C, Bertini M et al. Telecardiology and remote monitoring of implanted electrical devices: The potential for fresh clinical care perspectives. J Gen Intern Med 2008;23(Suppl 1):73-7
257. Boriani G, Da Costa A, Ricci RP, Quesada A, Favale S, Iacopino S et al. The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) randomized controlled trial: phase 1 results on dynamics of early intervention with remote monitoring. J Med Internet Res 2013;15:e167
258. Boriani G. Remote monitoring of cardiac implantable electrical devices in Europe: quo vadis? Europace 2015;17:674-6.